"Active" cancer immunotherapy by anti-met antibody gene transfer

Elisa Vigna, Giovanni Pacchiana, Massimiliano Mazzone, Cristina Chiriaco, Lara Fontani, Cristina Basilico, Selma Pennacchietti, Paolo M. Comoglio

Research output: Contribution to journalArticlepeer-review


Gene therapy provides a still poorly explored opportunity to treat cancer by "active" immunotherapy as it enables the transfer of genes encoding antibodies directed against specific oncogenic proteins. By a bidirectional lentiviral vector, we transferred the cDNA encoding the heavy and light chains of a monoclonal anti-Met antibody (DN-30) to epithelial cancer cells. In vitro, the transduced cells synthesized and secreted correctly assembled antibodies with the expected high affinity, inducing down-regulation of the Met receptor and strong inhibition of the invasive growth response. The inhibitory activity resulted (a) from the interference of the antibody with the Met receptor intracellular processing ("cell autonomous activity," in cis) and (b) from the antibody-induced cleavage of Met expressed at the cell surface ("bystander effect," in trans). The monoclonal antibody gene transferred into live animals by systemic administration or by local intratumor delivery resulted in substantial inhibition of tumor growth. These data provide proof of concept both for targeting the Met receptor and for a gene transfer-based immunotherapy strategy.

Original languageEnglish
Pages (from-to)9176-9183
Number of pages8
JournalCancer Research
Issue number22
Publication statusPublished - Nov 15 2008

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of '"Active" cancer immunotherapy by anti-met antibody gene transfer'. Together they form a unique fingerprint.

Cite this